Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CTLA-4/PD-1 expressing meso-CAR-T in advanced solid tumors
NCT03182803Phase 2Unknown
- Start
- Jun 2017
- Primary completion
- Jan 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CTLA-4/PD-1 antibodies expressing mesoCAR-T in solid tumor. Primary endpoint: Incidence of treatment-related adverse events at 2 years. Status: unknown.
02
Drugs
CTLA-4/PD-1 antibodies expressing mesoCAR-T
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03182803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03182803.